We are a leading provider of preclinical development services for cancer therapeutics, cancer vaccines, and chemopreventive agents for private companies and the National Cancer Institute. SRI has a significant track record in discovering potential new therapeutics as treatments for cancer. We continue to discover new entities that show promise as future drugs -- for example, green tea analogs as cancer therapeutics and chemopreventives.

Media Resources

Press releases
SRI International Awarded a Department of Defense "Laboratory-Clinical Transition" Grant to Advance SRI’s Novel Anticancer Agents for Prostate Cancer Treatment

FDA Approves Pralatrexate for Treatment of Peripheral T-Cell Lymphoma; Drug Discovered and Developed by SRI International, Memorial Sloan-Kettering Cancer Center, and Southern Research Institute

SRI International Announces Selection by the National Cancer Institute as a Chemical Biology Consortium Center

SRI International and Pentax Corporation Develop Biomarkers for Oncology Diagnostics

SRI International Cancer Drug SR 16388 Selected by the National Cancer Institute as Promising Treatment for Advanced Prostate Cancer

Promising Cancer Therapeutics Developed by SRI International

SRI International Celebrates 50 Years of Drug Discovery and Development Contributions

Second Phase Begins: NIGMS Grant for Mathematical Modeling of Biological Systems

Pathway Logic Tools Model Cellular Networks for Breast Cancer Research

National Cancer Institute Selects SRI's Novel AKT Inhibitor Drug for Further Development as Cancer Chemopreventative

Websites
SRI's Biosciences Division

Background on cancer therapeutics

Expert sources
Walter Moos
Lidia Sambucetti

| Contact SRI Public Relations to request an interview |